[The current state and issues of medical treatment for age-related macular degeneration].
Ishida
Susumu
S
ishidasu@sc.itc.keio.ac.jp
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D000069579:Ranibizumab; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042442:Vascular Endothelial Growth Factors; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab